Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Fish and Richardson
Express Scripts
Moodys
Baxter
Teva
Accenture
Merck
Deloitte
Cantor Fitzgerald

Generated: July 15, 2018

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 203093

« Back to Dashboard

NDA 203093 describes VITEKTA, which is a drug marketed by Gilead Sciences Inc and is included in one NDA. There are three patents protecting this drug. Additional details are available on the VITEKTA profile page.

The generic ingredient in VITEKTA is elvitegravir. There are six drug master file entries for this compound. Additional details are available on the elvitegravir profile page.
Summary for 203093
Tradename:VITEKTA
Applicant:Gilead Sciences Inc
Ingredient:elvitegravir
Patents:3
Formulation / Manufacturing:see details
Generic Entry Opportunity Date for 203093
Generic Entry Date for 203093*:
Constraining patent/regulatory exclusivity:
Dosage::
TABLET;ORAL

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Profile for product number 001

Active Rx/OTC/Discontinued:DISCNDosage:TABLET;ORALStrength85MG
Approval Date:Sep 24, 2014TE:RLD:Yes
Patent:➤ Sign UpPatent Expiration:Aug 27, 2026Product Flag?YSubstance Flag?YDelist Request?
Patented Use:TREATMENT OF HIV INFECTION
Patent:➤ Sign UpPatent Expiration:Oct 26, 2026Product Flag?YSubstance Flag?YDelist Request?
Patented Use:TREATMENT OF HIV INFECTION
Patent:➤ Sign UpPatent Expiration:Oct 26, 2026Product Flag?YSubstance Flag?YDelist Request?

Complete Access Available with Subscription

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Moodys
Johnson and Johnson
Healthtrust
Accenture
Colorcon
Covington
Citi
US Army
US Department of Justice

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.